Vaccines – Therapeutics – Anti Microbial Peptides

According to the US FDA, antimicrobial resistance is recognized as a growing global threat. Via horizontal gene transfer, antibiotic resistance genes may be transferred to humans, thereby reducing the effectiveness of antimicrobial drugs for treating human disease.

ARTES´ provides access to its proprietary yeast technology platform completely void of any antibiotic resistance marker throughout the full manufacturing process of veterinary products, such as vaccines, therapeutic proteins and anti microbial peptides. Together with allergen and toxin free production cell lines, ARTES ensures safe veterinary products.

The METAVAX® technology platform is ideally suited for development of veterinary vaccines by presentation of target antigens in form of chimeric virus like particles (VLPs). This approach is a.o. recognized by the EU, funding the development of novel METAVAX® based veterinary vaccines (Plurivax).